CoChat

In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

BACKGROUND Accumulating evidence suggests that α-synuclein aggregates-a defining pathology of Parkinson's disease-display cell-to-cell transmission. α-synuclein aggregation is hypothesised to start in autonomic nerve terminals years before the appearance of motor symptoms, and subsequently spread via autonomic nerves to the spinal cord and brainstem. To assess this hypothesis, we investigated sympathetic, parasympathetic, noradrenergic, and dopaminergic innervation in patients with idiopathic rapid eye movement (REM) sleep behaviour disorder, a prodromal phenotype of Parkinson's disease. METHODS In this prospective, case-control study, we recruited patients with idiopathic REM sleep behaviour disorder, confirmed by polysomnography, without clinical signs of parkinsonism or dementia, via advertisement and through sleep clinics in Denmark. We used 11C-donepezil PET and CT to assess cholinergic (parasympathetic) gut innervation, 123I-metaiodobenzylguanidine (MIBG) scintigraphy to measure cardiac sympathetic innervation, neuromelanin-sensitive MRI to measure integrity of pigmented neurons of the locus coeruleus, 11C-methylreboxetine (MeNER) PET to assess noradrenergic nerve terminals originating in the locus coeruleus, and 18F-dihydroxyphenylalanine (DOPA) PET to assess nigrostriatal dopamine storage capacity. For each imaging modality, we compared patients with idiopathic REM sleep behaviour disorder with previously published reference data of controls without neurological disorders or cognitive impairment and with symptomatic patients with Parkinson's disease. We assessed imaging data using one-way ANOVA corrected for multiple comparisons. FINDINGS Between June 3, 2016, and Dec 19, 2017, we recruited 22 consecutive patients with idiopathic REM sleep behaviour disorder to the study. Compared with controls, patients with idiopathic REM sleep behaviour disorder had decreased colonic 11C-donepezil uptake (-0·322, 95% CI -0·112 to -0·531; p=0·0020), 123I-MIBG heart:mediastinum ratio (-0·508, -0·353 to -0·664; p<0·0001), neuromelanin-sensitive MRI locus coeruleus:pons ratio (-0·059, -0·019 to -0·099; p=0·0028), and putaminal 18F-DOPA uptake (Ki; -0·0023, -0·0009 to -0·0037; p=0·0013). No between-group differences were detected between idiopathic REM sleep behaviour disorder and Parkinson's disease groups with respect to 11C-donepezil (p=0·39), 123I-MIBG (p>0·99), neuromelanin-sensitive MRI (p=0·96), and 11C-MeNER (p=0·56). By contrast, 15 (71%) of 21 patients with idiopathic REM sleep behaviour disorder had 18F-DOPA Ki values within normal limits, whereas all patients with Parkinson's disease had significantly decreased 18F-DOPA Ki values when compared with patients with idiopathic REM sleep behaviour disorder (p<0·0001). INTERPRETATION Patients with idiopathic REM sleep behaviour disorder had fully developed pathology in the peripheral autonomic nervous system and the locus coeruleus, equal to that in diagnosed Parkinson's disease. These patients also showed noradrenergic thalamic denervation, but most had normal putaminal dopaminergic storage capacity. This caudorostral gradient of dysfunction supports the hypothesis that α-synuclein pathology in Parkinson's disease initially targets peripheral autonomic nerves and then spreads rostrally to the brainstem. FUNDING Lundbeck Foundation, Jascha Foundation, and the Swiss National Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(18)30162-5

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The five imaging modalities and their relationship to Braak stage structures involved in PD are denoted by roman numerals. I. 11 C-donepezil PET signal of the intestine is a marker of decreased acetylcholine esterase activity, reflecting cholinergic innervation including parasympathetic innervation from the dorsal motor nucleus of the vagus (DMV). Arrows indicate the small intestine. 123 I-MIBG is a validated tracer of sympathetic cardiac innervation II. 11 CMeNER measures the availability of noradrenaline transporters in terminals originating from the locus coeruleus (LC). The integrity of the pigmented cell bodies of the LC is estimated by neuromelanin-sensitive MRI (arrows). III. Striatal dopamine storage capacity of projections from the substantia nigra (SN) is measured with 18 F-DOPA PET.
Figure 1 The five imaging modalities and their relationship to Braak stage structures involved in PD are denoted by roman numerals. I. 11 C-donepezil PET signal of the intestine is a marker of decreased acetylcholine esterase activity, reflecting cholinergic innervation including parasympathetic innervation from the dorsal motor nucleus of the vagus (DMV). Arrows indicate the small intestine. 123 I-MIBG is a validated tracer of sympathetic cardiac innervation II. 11 CMeNER measures the availability of noradrenaline transporters in terminals originating from the locus coeruleus (LC). The integrity of the pigmented cell bodies of the LC is estimated by neuromelanin-sensitive MRI (arrows). III. Striatal dopamine storage capacity of projections from the substantia nigra (SN) is measured with 18 F-DOPA PET.CC-BY-NC-ND · From the PDF
Figure 2 Representative images from healthy controls (HC), iRBD, and PD patients with the five imaging modalities. Individual cases are representative of the group mean within the respective groups. A. 11 C-donepezil PET/CT. Note lower donepezil uptake in the colon in iRBD and PD. Arrows denote transverse colon. B. 123 I-MIBG scintigraphy of the heart (arrow). Note completely absent heart uptake in iRBD and PD. C. Neuromelanin (NM) MRI of locus coeruleus (arrows). Note lower locus coeruleus signal in iRBD and PD. D. 11 CMeNER PET. Thalamic MeNER binding potential (BPND), shown by arrows, is decreased in iRBD and PD. E. 18 F-DOPA PET. Putamen FDOPA signal (arrows) is mildly decreased in some iRBD cases, but markedly decreased in PD.
Figure 2 Representative images from healthy controls (HC), iRBD, and PD patients with the five imaging modalities. Individual cases are representative of the group mean within the respective groups. A. 11 C-donepezil PET/CT. Note lower donepezil uptake in the colon in iRBD and PD. Arrows denote transverse colon. B. 123 I-MIBG scintigraphy of the heart (arrow). Note completely absent heart uptake in iRBD and PD. C. Neuromelanin (NM) MRI of locus coeruleus (arrows). Note lower locus coeruleus signal in iRBD and PD. D. 11 CMeNER PET. Thalamic MeNER binding potential (BPND), shown by arrows, is decreased in iRBD and PD. E. 18 F-DOPA PET. Putamen FDOPA signal (arrows) is mildly decreased in some iRBD cases, but markedly decreased in PD.CC-BY-NC-ND · From the PDF
Image 3
CC-BY-NC-ND · From the PDF
Image 4
CC-BY-NC-ND · From the PDF
Image 5
CC-BY-NC-ND · From the PDF
Figure 5 The figure shows pathology indices (mean±SEM) of the present iRBD imaging data (black circles) listed according to PD Braak stage structures. For each imaging modality the healthy control (C) average is set at 0% and PD average at 100%. Grey circles show pathology indices from two previous MIBG studies 19,31 (a & b), and two dopamine transporter SPECT studies 32,33 (c & d). The four grey points in b show the MIBG pathology index of iRBD patients compared to H&Y stage I through IV PD patients (roman numerals: I, II, III, IV). Note that the H&Y I index was actually 300% (denoted by * and up-arrow). That particular MIBG study demonstrated that iRBD patients show more severe cardiac sympathetic denervation than H&Y I-II PD patients (MIBG index >100%). Similarly, our iRBD group showed a donepezil PET index of 157% when compared to our early stage PD patients. In one dopamine transporter SPECT studies, iRBD patients were compared to de novo H&Y I patients (c), and in another iRBD cases were compared to PD patients with and without RBD (depicted with + and - RBD). [DON: donepezil colon values, NM: neuromelanin MRI]
Figure 5 The figure shows pathology indices (mean±SEM) of the present iRBD imaging data (black circles) listed according to PD Braak stage structures. For each imaging modality the healthy control (C) average is set at 0% and PD average at 100%. Grey circles show pathology indices from two previous MIBG studies 19,31 (a & b), and two dopamine transporter SPECT studies 32,33 (c & d). The four grey points in b show the MIBG pathology index of iRBD patients compared to H&Y stage I through IV PD patients (roman numerals: I, II, III, IV). Note that the H&Y I index was actually 300% (denoted by * and up-arrow). That particular MIBG study demonstrated that iRBD patients show more severe cardiac sympathetic denervation than H&Y I-II PD patients (MIBG index >100%). Similarly, our iRBD group showed a donepezil PET index of 157% when compared to our early stage PD patients. In one dopamine transporter SPECT studies, iRBD patients were compared to de novo H&Y I patients (c), and in another iRBD cases were compared to PD patients with and without RBD (depicted with + and - RBD). [DON: donepezil colon values, NM: neuromelanin MRI]CC-BY-NC-ND · From the PDF
Supplementary Figure 2. The MRI neuromelanin LC/pons ratio in healthy controls (HC), iRBD, and PD patients with and without RBD. No significant differences were seen between iRBD and either PD group (iRBD vs. PD-RBD: p=0 · 344, iRBD vs. PD+RBD: p=0 · 662). However, the iRBD group displayed significantly lower values than the HC group (p=0 · 004). [Dotted line denotes 1 SD below control mean].
Supplementary Figure 2. The MRI neuromelanin LC/pons ratio in healthy controls (HC), iRBD, and PD patients with and without RBD. No significant differences were seen between iRBD and either PD group (iRBD vs. PD-RBD: p=0 · 344, iRBD vs. PD+RBD: p=0 · 662). However, the iRBD group displayed significantly lower values than the HC group (p=0 · 004). [Dotted line denotes 1 SD below control mean].CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 317

Metadata

Authors
Knudsen, K., Fedorova, T. D., Hansen, A. K., Sommerauer, M., Otto, M., Svendsen, K. B., Nahimi, A., Stokholm, M. G., Pavese, N., Beier, C. P., Brooks, D. J., & Borghammer, P.
Affiliations
  • Aarhus University Hospital (DK)
  • University of Southern Denmark (DK)
Corresponding author
Borghammer, Per
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2018-07
Volume
17
Issue
7
Pages
618-628
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2803083570
Cited by
309
References
51
Citations by year
2026: 16 · 2025: 25 · 2024: 47 · 2023: 37 · 2022: 50 · 2021: 57 · 2020: 29 · 2019: 33 · 2018: 15
FWCI
22.75
Type
journal article
Language
en
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by-nc-nd)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
Funders
  • Jascha Fonden
  • Lundbeckfonden
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
REM sleep behavior disorder, alpha-synuclein aggregation, cell-to-cell transmission, cardiac sympathetic innervation, noradrenergic terminals, locus coeruleus, nigrostriatal dopamine, 123I-MIBG scintigraphy, neuromelanin-sensitive MRI
MeSH terms
Aged, Denmark, Female, Heart, Humans, Locus Coeruleus, Magnetic Resonance Imaging, Male, Middle Aged, Parkinson Disease, Prospective Studies, Sympathetic Nervous System, Case-Control Studies, Polysomnography, Presynaptic Terminals, REM Sleep Behavior Disorder, Positron-Emission Tomography, Multimodal Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. https://app.cochat.ai/papers/10.1016/s1474-4422(18)30162-5
The paper
Knudsen, K., Fedorova, T. D., Hansen, A. K., Sommerauer, M., Otto, M., Svendsen, K. B., Nahimi, A., Stokholm, M. G., Pavese, N., Beier, C. P., Brooks, D. J., & Borghammer, P. (2018). In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(18)30162-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.